Table 5.

Secondary Efficacy Outcomes at Week 12: Patients With Baseline NIHSS ≥8 % of Patients LOCF

Placebo n=84500 mg Citicoline n=208
Death25%21%P>0.1
Barthel ≥9521%33%P=0.05
Rankin ≤111%19%P=0.07
NIHSS ≤111%19%P=0.08
Hospital stay: d, median98P>0.1